Association of OPN overexpression with tumor stage, differentiation, metastasis and tumor progression in human laryngeal squamous cell carcinoma

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 5, 2015, Pages 7116-7124

  Chen, Jianqiu ^a   Zhu, Chunsheng ^a   He, Zhen ^a   Geng, Min ^a   Li, Guojun ^b   Tao, Xiaofeng ^c   Zhang, Fenghua ^d  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d HEBEI GENERAL HOSPITAL   (China)

Author keywords

Laryngeal squamous cell carcinoma; Osteopontin; P53; RNA interference

Indexed keywords

LENTIVIRUS VECTOR; OSTEOPONTIN; PROTEIN P53; SHORT HAIRPIN RNA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL INVASION ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MTS ASSAY; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

LENTIVIRUS;

EID: 84937041850     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. [1] Vokes EE, Weichselbaum RR, Lippman SM and Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184-194.
2. [2] Mao L, Hong WK and Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004; 5: 311-316.
3. [3] Licitra L, Bernier J, Grandi C, Locati L, Merlano M, Gatta G and Lefebvre JL. Cancer of the larynx. Crit Rev Oncol Hematol 2003; 47: 65-80.
4. [4] Sotiriou C, Lothaire P, Dequanter D, Cardoso F and Awada A. Molecular profiling of head and neck tumors. Curr Opin Oncol 2004; 16: 211-214.
5. [5] Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001; 1552: 61-85.
6. [6] Rittling SR and Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90: 1877-1881.
7. [7] Rangaswami H, Bulbule A and Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006; 16: 79-87.
8. [8] Wai PY and Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008; 27: 103-118.
9. [9] Weber GF, Ashkar S, Glimcher MJ and Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-512.
10. [10] Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K and Murakami M. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999; 59: 219-226.
11. [11] Crawford HC, Matrisian LM and Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206-5215.
12. [12] Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF and Yeatman TJ. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10: 184-190.
13. [13] Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ and Findlay DM. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 1997; 73: 812-815.
14. [14] Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW and Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-1679.
15. [15] Fedarko NS, Jain A, Karadag A, Van Eman MR and Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060-4066.
16. [16] Hotte SJ, Winquist EW, Stitt L, Wilson SM and Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002; 95: 506-512.
17. [17] Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue H, Kondo M, Mori Y, Tanaka E and Imamura M. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 2005; 68: 285-292.
18. [18] Li Y, Li L, Wang JT, Kan X and Lu JG. Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol 2012; 29: 1429-1434.
19. [19] El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M and Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006; 17: 463-474.
20. [20] Meerovitch K, Bergeron F, Leblond L, Grouix B, Poirier C, Bubenik M, Chan L, Gourdeau H, Bowlin T and Attardo G. A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic en-dothelial cells on type I collagen. Vascul Pharmacol 2003; 40: 77-89.
21. [21] van Houten VM, Tabor MP, van den Brekel MW, Kummer JA, Denkers F, Dijkstra J, Leemans R, van der Waal I, Snow GB and Brakenhoff RH. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol 2002; 198: 476-486.
22. [22] Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J 2006; 85: 74.
23. [23] Bache M, Reddemann R, Said HM, Holzhausen HJ, Taubert H, Becker A, Kuhnt T, Hansgen G, Dunst J and Vordermark D. Immunohis-tochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-re-lated markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys 2006; 66: 1481-1487.
24. [24] Tong X, Li K, Luo Z, Lu B, Liu X, Wang T, Pang M, Liang B, Tan M and Wu M. Decreased TIP30 expression promotes tumor metastasis in lung cancer. Am J Pathol 2009; 174: 1931-1939.
25. [25] Hoffman HT, Karnell LH, Funk GF, Robinson RA and Menck HR. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1998; 124: 951-962.
26. [26] Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Van Der Wal JE, Snow GB, Leemans CR and Braakhuis BJ. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol 2002; 161: 1051-1060.
27. [27] Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
28. [28] Eto M, Kodama S, Nomi N, Uemura N and Suzuki M. Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx 2007; 34: 343-346.
29. [29] Staibano S, Merolla F, Testa D, Iovine R, Mascolo M, Guarino V, Castellone MD, Di Benedetto M, Galli V and Motta S. OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. Br J Cancer 2007; 97: 1545-1551.
30. [30] Celetti A, Testa D, Staibano S, Merolla F, Guarino V, Castellone MD, Iovine R, Mansueto G, Somma P and De Rosa G. Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res 2005; 11: 8019-8027.
31. [31] Hollstein M, Sidransky D, Vogelstein B and Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
32. [32] Morimoto I, Sasaki Y, Ishida S, Imai K and Tokino T. Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer 2002; 33: 270-278.
33. [33] Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A and Lucchi M. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers 2010; 25: 164-170.
34. [34] Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, Arivazhagan A, Balasubramaniam A, Hegde AS and Chandramouli BA. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 2010; 19: 1409-1422.
35. [35] Van den Haute C, Eggermont K, Nuttin B, Debyser Z and Baekelandt V. Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. Hum Gene Ther 2003; 14: 1799-1807.
36. [36] Lebedev TD, Spirin PV and Prassolov VS. Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors. Acta Naturae 2013; 5: 7-18.